Cell Therapeutics To Launch First Commercial Product Trisenox With 16 Reps

Cell Therapeutics will launch its first commercial product Trisenox for treatment of acute promyelocytic leukemia with an internal oncology sales force of 16 reps, CTI CEO James Bianco, MD, told a Sept. 27 conference call.